Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesCompany aims to accelerate access to much-needed biosimilar to reference ...

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy ...

Lundbeck has stopped development of a subcutaneous formulation of its migraine drug Lu AG09222 as the Danish drugmaker switches its focus to intravenous delivery after seeing phase 2b data, delaying ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown why it made small cell lung cancer a priority for its PD-L1xVEGF-A ...

Rayes was head of commercial at ChemoCentryx for the Tavneos launch, giving her a starring role in a product rollout that ultimately persuaded Amgen to ... the company named (PDF) Tavneos as ...

Based on indication, Global Nanomedicine Therapeutics Market is divided into Oncology, Infectious Disease, Cardiology, and Neurological Disease segments. The oncology segment holds the largest share, ...

North America Cancer Therapy Market Size Set Expands at Significant CAGR of 8.15% During 2024-2030 to Reach USD 5.87 Billion by 2030 Request To Download Free Sample of This Strategic Report @ ...

Lonza Group AG / Key word (s): Annual Results/Sustainability Lonza Publishes Invitation to the 2025 Annual General Meeting and 2024 Annual and Sustainability Reports 03-Apr-2025 / 07:00 CET/CEST ...

The global US Autoinjectors Market is projected to expand to a value of US$1.45 billion in 2030 from US$0.65 billion in 2024, with a significant ...

Amgen has gotten caught up in the broader market decline, but its business is unscathed. Its obesity drug sales are about to boom, making the stock look like a buy.

In the latest trading session, Amgen (AMGN) closed at $318.65, marking a +0.47% move from the previous day. The stock outpaced the S&P 500's daily loss of 1.07%. Elsewhere, the Dow lost 0.62% ...